Awakn Life Sciences (XCNQ:AWKN) EBIT : C$-4.59 Mil (TTM As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Awakn Life Sciences EBIT?

Awakn Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2024 was C$-0.84 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2024 was C$-4.59 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Awakn Life Sciences's annualized ROC % for the quarter that ended in Jan. 2024 was -5,181.54%. Awakn Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -336,800.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Awakn Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -126.50%.

Awakn Life Sciences EBIT Historical Data

The historical data trend for Awakn Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Awakn Life Sciences EBIT Chart

Awakn Life Sciences Annual Data

Trend

Jan21

Jan22

Jan23

Jan24

EBIT

-1.10

-16.27

-5.28

-3.93

Awakn Life Sciences Quarterly Data
	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBIT	Get a 7-Day Free Trial								-1.31	-1.61	-1.46	-0.68	-0.84

Competitive Comparison of Awakn Life Sciences's EBIT

For the Biotechnology subindustry, Awakn Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Awakn Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Awakn Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Awakn Life Sciences's EV-to-EBIT falls into.

Awakn Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.59 Mil.

Awakn Life Sciences (XCNQ:AWKN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Awakn Life Sciences's annualized ROC % for the quarter that ended in Jan. 2024 is calculated as:

	ROC % (Q: Jan. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2023 )	+	Invested Capital (Q: Jan. 2024 ))	/ count )
=	-3.368 * ( 1 - 0% )	/	( (0.075	+	0.055)	/ 2 )
=	-3.368	/	0.065
=	-5,181.54 %

where

	Invested Capital		(Q: Oct. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.091	-	2.016	-	( 0.555	-	max(0, 2.039	-	1.039	+	0.555	))
=	0.075

	Invested Capital		(Q: Jan. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.543	-	2.066	-	( 0.407	-	max(0, 2.074	-	0.496	+	0.407	))
=	0.055

Note: The Operating Income data used here is four times the quarterly (Jan. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Awakn Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jan. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Oct. 2023		Q: Jan. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.368	/	( ( (0.001 + max(-1.686, 0))	+	(0.001 + max(-1.999, 0)) )	/	2 )
=	-3.368	/	( ( 0.001	+	0.001 )	/	2 )
=	-3.368	/	0.001
=	-336,800.00 %

where Working Capital is:

	Working Capital		(Q: Oct. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.212	+	0	+	0.141)	-	(2.016	+	0.022	+	0.0010000000000003)
=	-1.686

	Working Capital		(Q: Jan. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.007	+	0	+	0.068)	-	(2.066	+	0.007	+	0.00099999999999989)
=	-1.999

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Awakn Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jan. 2024 )
	=	-4.592	/	3.630
	=	-126.50 %

Awakn Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Awakn Life Sciences (XCNQ:AWKN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (XCNQ:AWKN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

AWKNF:USA 954:Germany

Address

301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2

Website

https://www.awaknlifesciences.com

Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.

Awakn Life Sciences (XCNQ:AWKN) Headlines

No Headlines